LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

Strona główna・Stock List・Krystal Biotech Inc

Krystal Biotech Inc

Open

SectorHealthcare

298.39 -2.53

Buy Sell

Overview

Share price change

24h

Current

Min

297.98

Max

306.33

Key metrics
By Trading Economics
Income	4.5M 56M
Sales	9.3M 116M
P/E Sector Avg	41.829 51.415
EPS	1.83
Profit margin	48.069
Employees	295
EBITDA	16M 55M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+3.17% upside

Dividends
By Dow Jones
Next Earnings	3 sie 2026

Market Stats
By TradingEconomics
Market Cap	1.2B 9.2B
Previous open	300.92
Previous close	298.39

News Sentiment

By Acuity

20%

80%

28 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

133.221 / 169.73 Support & Resistance

Krystal Biotech Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 maj 2026, 23:53 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 maj 2026, 22:47 UTC

Hot Stocks

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 maj 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 maj 2026, 22:00 UTC

Major Market Movers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 maj 2026, 18:09 UTC

Major Market Movers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 maj 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 maj 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17 maj 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 maj 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 maj 2026, 23:07 UTC

Acquisitions, Mergers, Takeovers

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 maj 2026, 23:06 UTC

Acquisitions, Mergers, Takeovers

UOB: Share Sale Agreements Entered With Singland Properties

17 maj 2026, 23:05 UTC

Acquisitions, Mergers, Takeovers

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 maj 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 maj 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Acquire Stake for $389 Million

17 maj 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 maj 2026, 16:27 UTC

Acquisitions, Mergers, Takeovers

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 maj 2026, 15:26 UTC

Acquisitions, Mergers, Takeovers

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 maj 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 maj 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 maj 2026, 21:59 UTC

Acquisitions, Mergers, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 maj 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 maj 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 maj 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 maj 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 maj 2026, 20:19 UTC

Hot Stocks

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 maj 2026, 19:41 UTC

Acquisitions, Mergers, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 maj 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 maj 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 maj 2026, 18:35 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Peer Comparison

Price change

Krystal Biotech Inc Forecast

Price Target

By TipRanks

3.17% upside

12 Months Forecast

Average 316 USD 3.17%

High 378 USD

Low 284 USD

Based on 10 Wall Street analysts offering 12 month price targets forKrystal Biotech Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Krystal Biotech Inc - Dist in the past 3 months.

Technical Score

By Trading Central

133.221 / 169.73Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

28 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.